Metabolic Health
Beyond Weight Loss: What the Latest GLP-1 Evidence Says About Liver, Kidney, Heart, and Cost
Fresh 2025 reviews map semaglutide's reach into fatty liver disease, cardiovascular risk, kidney protection — and the economics of treating obesity at scale. The signals are real, but the picture is still filling in.